VAERS Explorer
Back to explore

Report #2836925

Received Apr 21, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Male
Age
56 yrs
State
NC
Recovered
Not recovered
Vaccinated
Jan 21, 2025
Onset
Jan 24, 2025
Days to onset
3
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
VARZOSZOSTER (SHINGRIX)GLAXOSMITHKLINE BIOLOGICALS1Fj9a7—

Symptoms (1)

Rash

Symptom narrative

Full body rash; This non-serious case was reported by a physician via sales rep and described the occurrence of generalized rash in a 56-year-old male patient who received Herpes zoster (Shingrix) (batch number Fj9a7, expiry date 16-JUL-2025) for prophylaxis. On 21-JAN-2025, the patient received the 1st dose of Shingrix. On 24-JAN-2025, 3 days after receiving Shingrix, the patient experienced generalized rash (Verbatim: Full body rash). The outcome of the generalized rash was not resolved. It was unknown if the reporter considered the generalized rash to be related to Shingrix. It was unknown if the company considered the generalized rash to be related to Shingrix. Additional Information: GSK Receipt Date: 14-APR-2025 The patient experienced full body rash.